The company's shares grew 28 percent in September after it terminated a licensing deal with BioMérieux and regained control of certain intellectual property.
CareDx led the Index for the month — the firm's shares rose 81 percent on the strength of its second quarter earnings report.
Proceeds from the offering, expected to close on or about Aug. 14, could be used to fund acquisitions, to repay existing debts, or for working capital.
Natera led the Index for the second month in a row after it announced that it intended to raise $75 million in a public stock offering.
Natera led the Index with a 61 percent increase in stock price, driven by the firm's announcement that it was entering the transplantation market.
The study solidified how doctors should interpret and act upon an intermediate result from the breast cancer risk test in how to treat early-stage patients.
Though the Dow, the Nasdaq, and the Nasdaq Biotechnology Index all rose in May, they were outperformed by the GenomeWeb Index.
Positive first quarter earnings reports lifted many stocks of life science tools firms even as the broader biotechnology market suffered.
The decline matched the struggles of the broader stock market, though bright spots could be found with GenMark, Quidel, and NanoString all having good months.
The firm increased the number of shares it was offering after its stock price fell sharply this week.
The Hill reports President Donald Trump issued an executive directing federal agencies to cut the number of board and advisory committees they have.
The New York Times reports that researchers are combining tools to more quickly develop crops to feed a growing population and cope with shifting climates.
Scientists in Canada are looking to the UK's plan to sequence children with rare conditions for inspiration, the National Post reports.
In PNAS this week: copy number changes arose during polar bear evolution, genomic and transcriptomic analysis of the Siberian hamster, and more.